drugset / Trial / NCT01668797

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

NCT01668797 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia.

Timeline

Start
2012-10
Primary completion
2015-01
Completion
2015-02

Outcome

Met primary endpoint

paper The final analysis showed that time to impending relapse was statistically significantly delayed with brexpiprazole treatment compared with placebo (P<.0001, log-rank test). PMID 27566723 ↗

paper The hazard ratio for the final analysis was 0.292 (95% confidence interval: 0.156, 0.548); PMID 27566723 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 1 mg —
Subject Brexpiprazole Small molecule 4 mg —

Indications